June 2020 FDA Recall Metformin Hydrochloride Extended Release by Pd-rx Pharmaceuticals, Inc.
D-1333-2020 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Pd-rx Pharmaceuticals, Inc. on June 5, 2020 for the product Metformin Hydrochloride Extended Release. The FDA reported the reason for recall as cgmp deviations. The product was distributed in United States. and the recall is currently terminated.

Recall Number: D-1333-2020

Reason for Recall
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Initiated
06-05-2020
Reported
07-01-2020
Quantity
1969 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
PD-Rx Pharmaceuticals, Inc.
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
metFORMIN HCL ER 500 mg, a) 30 tablets (NDC 72789-009-30); b) 60 tablets (NDC 72789-009-60); c) 90 tablets (NDC 72789-009-90); d) 180 tablets (NDC 72789-009-93); e) 100 tablets (NDC 49483-0623-01) bottles, Rx only PD-Rx Pharmaceuticals Incorporated, Oklahoma City, OK 73127

Batch or Lot Expiration Information

Lot# Lots: a) A20B02, I19D03, J19A98, K19E32, L19C86 Exp. 12/31/2020; b) I19D55, I19F50, K19A18, K19D87, L19B34, L19D23, L19E74 Exp. 12/31/2020; c) I19E91, I19F33, J19B88, J19E70, K19D26, L19A65 Exp. 12/31/2020; d) I19C21 Exp. 08/21/2020, I19C57, J19C21, J19C67, K19B53, L19C77, L19E44 Exp. 12/31/2020; e) XP9004 Exp. 12/31/2020